8-K
filed November 26, 2025, 6:59 PM ET
ticker RXRX
CIK 0001601830
other material
confidence high
sentiment neutral
materiality 0.50
Recursion issues 7.1M shares to Tempus AI for license fees; registers for resale
RECURSION PHARMACEUTICALS, INC.
- Issued 7,088,742 Class A shares to Tempus AI on Nov 24, 2025 as payment for annual license fees.
- Shares registered for resale via prospectus supplement filed Nov 26, 2025 under existing shelf registration.
- Issuance stems from Master Agreement dated Nov 9, 2023, as previously disclosed in an 8-K.
- Resale registration may allow Tempus to sell shares, creating potential dilution for existing holders.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001601830-25-000172
- form_type
- 8-K
- ticker
- RXRX
- cik
- 0001601830
- company_name
- RECURSION PHARMACEUTICALS, INC.
- filed_at
- 2025-11-26T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:39.885116+00:00
- generated_at
- 2026-05-16T16:29:29.358479+00:00
- sec_items
- ["8.01", "9.01"]
- event_type
- other_material
- sentiment
- neutral
- materiality_score
- 0.5
- calibrated_materiality_score
- 0.5
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001601830-25-000172
- json_url
- https://secwatch.observer/filing/0001601830-25-000172.json
- markdown_url
- https://secwatch.observer/filing/0001601830-25-000172.md
- text_url
- https://secwatch.observer/filing/0001601830-25-000172.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1601830/000160183025000172/0001601830-25-000172-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1601830/000160183025000172/rxrx-20251126.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
GIPR
Generation Income Properties prices $5.0M public offering of 23.8M shares and warrants at $0.21/unit
GENERATION INCOME PROPERTIES, INC.
June 1, 2026, 5:27 PM ET
other_material
Items 1.01, 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
MUX
McEwen receives $49.4M dividend from Minera Santa Cruz; total 2026 dividends now $58.2M
McEwen Inc.
June 1, 2026, 5:14 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
EMYB
Embassy Bancorp expands stock repurchase program by additional $5M
Embassy Bancorp, Inc.
June 1, 2026, 4:37 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CTXR
Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned
Citius Pharmaceuticals, Inc.
June 1, 2026, 4:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
CTOR
Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer
CITIUS ONCOLOGY, INC.
June 1, 2026, 4:30 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
SYRE
Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030
Spyre Therapeutics, Inc.
June 1, 2026, 4:01 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
ORKA
Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030
Oruka Therapeutics, Inc.
June 1, 2026, 4:01 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
VIASP
Via Renewables to redeem all 1,884,935 shares of its 8.75% Series A Preferred at $25.00 per share plus dividends
Via Renewables, Inc.
June 1, 2026, 3:06 PM ET
other_material
Items 8.01, 9.01
same SEC item: 8.01, 9.01
same event type: other_material
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.